Study Evaluating Enbrel (Etanercept) in Patients With Ankylosing Spondylitis
NCT00227227
Last updated date
ABOUT THIS STUDY
The purpose of this study is to investigate the incidence of adverse events for patients with
AS treated with Enbrel in usual care settings.
FOR MORE INFORMATION
Contact a representative by phone, email, or visiting the study website. Please see the references below:
By phone
Pfizer Clinical Trials Contact Center
1-800-718-1021
Eligibility Criteria
condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Ankylosing Spondylitis
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
Adult Trials: 18+ Years
18 + years
Inclusion Criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details
- Diagnosis of ankylosing spondylitis
Exclusion Criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details
- Contraindications according SmPC
NEED INFO?
Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative
TRY A NEW SEARCH
Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.
Based on your search, you may also be interested in
Ankylosing SpondylitisA Study of ARRY-371797 in Patients With Active Ankylosing Spondylitis
NCT00811499
- Los Angeles, California
- Chicago, Illinois
- Omaha, Nebraska
- Oklahoma City, Oklahoma
- Portland, Oregon
- Charleston, South Carolina
- Spokane, Washington
- Edmonton, Alberta
- Winnipeg, Manitoba
- Mississauga, Ontario
- Trois-Rivieres, Quebec
- Saskatoon, Saskatchewan
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Ankylosing SpondylitisTo Investigate Genetic Factors Associated With the Response to Anti-TNF Therapy in Patients With Early AS
NCT02311842
- Guangzhou, Guangdong
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Ankylosing SpondylitisStudy To Evaluate The Impact Of Early Initiation Of Biological Treatment With Ankylosing Spondylitis
NCT04507763
- Baghdad,
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Ankylosing SpondylitisA Study Of Celecoxib Versus Diclofenac In Patients With Ankylosing Spondylitis
NCT02528201
- Bekkestua,
- Bergen,
- Bergen,
- Bodø,
- Bærum Postterminal,
- Drammen,
- Gamle Fredrikstad,
- Hamar,
- Harstad,
- Haugesund,
- Horten,
- Jessheim,
- Kongsvinger,
- Kristiansand,
- Kristiansand,
- Lena,
- Levanger,
- Lillehammer,
- Mo I Rana,
- Oslo,
- Oslo,
- Oslo,
- Skien,
- Tiller,
- Tromsø,
- Trondheim,
- Ålesund,
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Advanced Information
| Descriptive Information | |||||||
|---|---|---|---|---|---|---|---|
| Brief Title | Study Evaluating Enbrel (Etanercept) in Patients With Ankylosing Spondylitis | ||||||
| Official Title | Observational Study With Enbrel (Etanercept) in Patients With Ankylosing Spondylitis | ||||||
| Brief Summary | The purpose of this study is to investigate the incidence of adverse events for patients with AS treated with Enbrel in usual care settings. | ||||||
| Detailed Description | Not Provided | ||||||
| Study Type | Observational | ||||||
| Study Design | Time Perspective: Prospective | ||||||
| Target Follow-Up Duration | Not Provided | ||||||
| Biospecimen | Not Provided | ||||||
| Sampling Method | Not Provided | ||||||
| Study Population | Not Provided | ||||||
| Condition | Ankylosing Spondylitis | ||||||
| Intervention | Not Provided | ||||||
| Study Groups/Cohorts | Not Provided | ||||||
| Publications * | Not Provided | ||||||
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline. | |||||||
| Recruitment Information | |||||||
| Recruitment Status | Completed | ||||||
| Estimated Enrollment | 750 | ||||||
| Original Enrollment | Same as current | ||||||
| Actual Study Completion Date | June 2007 | ||||||
| Primary Completion Date | Not Provided | ||||||
| Eligibility Criteria | Inclusion Criteria:
Exclusion Criteria:
| ||||||
| Sex/Gender |
| ||||||
| Ages | 18 Years and older (Adult, Older Adult) | ||||||
| Accepts Healthy Volunteers | No | ||||||
| Contacts | Contact information is only displayed when the study is recruiting subjects | ||||||
| Listed Location Countries | Germany | ||||||
| Removed Location Countries | |||||||
| Administrative Information | |||||||
| NCT Number | NCT00227227 | ||||||
| Other Study ID Numbers | 101540 | ||||||
| Has Data Monitoring Committee | Not Provided | ||||||
| U.S. FDA-regulated Product | Not Provided | ||||||
| IPD Sharing Statement | Not Provided | ||||||
| Responsible Party | Not Provided | ||||||
| Study Sponsor | Wyeth is now a wholly owned subsidiary of Pfizer | ||||||
| Collaborators | Not Provided | ||||||
| Investigators |
| ||||||
| PRS Account | Wyeth is now a wholly owned subsidiary of Pfizer | ||||||
| Verification Date | December 2007 | ||||||